ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051
18. Dezember 2024 04:00 ET
|
ENA Respiratory
When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of infection in influenza...
ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
05. September 2024 04:00 ET
|
ENA Respiratory
New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities ...
ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
27. August 2024 04:00 ET
|
ENA Respiratory
Advances a new formulation with improved stability in the clinicSingle ascending dose phase successfully completed, multiple ascending dose phase underway MELBOURNE, Australia, Aug. 27, 2024 (GLOBE...
ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering INNA-051, a First-in-Class Antiviral Innate Immunomodulator
08. Mai 2024 04:00 ET
|
ENA Respiratory
MELBOURNE, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated...
ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator
29. April 2024 04:00 ET
|
ENA Respiratory
MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated...
New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance
11. September 2023 06:30 ET
|
ENA Respiratory
– INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection MELBOURNE,...
ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections
29. August 2023 08:00 ET
|
ENA Respiratory
-- New $3.8 million DOD contract extension will fund non-clinical safety studies to support a three-month seasonal prophylaxis Phase 2b study in at-risk populations, comprising elderly individuals...
Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
13. Februar 2023 08:00 ET
|
ENA Respiratory
-- Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration. -- These results support the further...
Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections
30. Januar 2023 08:00 ET
|
ENA Respiratory
-- ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations---- Survey was conducted...
ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051
09. Januar 2023 08:00 ET
|
ENA Respiratory
-- Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats MELBOURNE, Australia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clinical-stage pharmaceutical company...